Literature DB >> 25369006

Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial.

Ali Mostafavi1, Mahmoud Solhi1, Mohammad-Reza Mohammadi1, Mehdi Hamedi1, Maryam Keshavarzi1, Shahin Akhondzadeh1.   

Abstract

Olanzapine is the frequently prescribed drug in children and adolescents with bipolar disorder, but unfortunately it has metabolic side-effects. On the other hand, in a number of melatonin studies on sleep cycle, regulation of metabolic abnormalities has been reported. Therefore, we aimed to study effects of melatonin in reducing metabolic side-effects of olanzapine in 11-17 year-old patients with bipolar disorder. Seventy-seven 11-17 year-old outpatients entered into the study after their initial diagnosis of bipolar mood disorder by a psychiatrist. After assessing inclusion and exclusion criteria, 48 patients consented to participate in the study. Of this number, 24 patients were allocated to olanzapine, lithium carbonate, and melatonin and 24 patients were allocated to olanzapine, lithium carbonate, and placebo. Young mania rating scale was performed at baseline. Before treatment initiation and at sixth and twelfth weeks after treatment, Lipid profile, Fasting Blood Sugar (FBS), Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were measured. ANOVA with repeated measure and independent sample t-test were used for data analysis. Nineteen patients in each group completed the study and yielded data for analysis.  ANOVA with repeated measure showed that FBS and Triglyceride (TG) (especially in boys) demonstrated greater increase in the placebo group compared to the melatonin group but the differences were not statistically significant. Melatonin significantly inhibited the rise in Total Cholesterol levels compared to placebo (P=0.032). Mean SBP rose more slowly in the melatonin group (1.05mmHg) compared to placebo (6.36 mmHg) (P=0.023). The trends in DBP did not show any significant pattern. Administration of melatonin along with olanzapine and lithium carbonate could significantly inhibit the rise in cholesterol level and SBP compared to placebo. The effect of melatonin on TG was more obvious in boys. Melatonin was more effective in prevention of SBP rise.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25369006

Source DB:  PubMed          Journal:  Acta Med Iran        ISSN: 0044-6025


  10 in total

Review 1.  Melatonin, mitochondria, and the metabolic syndrome.

Authors:  Daniel P Cardinali; Daniel E Vigo
Journal:  Cell Mol Life Sci       Date:  2017-08-17       Impact factor: 9.261

Review 2.  Melatonin in type 2 diabetes mellitus and obesity.

Authors:  Angeliki Karamitri; Ralf Jockers
Journal:  Nat Rev Endocrinol       Date:  2019-02       Impact factor: 43.330

Review 3.  Melatonin as a Potential Agent in the Treatment of Sarcopenia.

Authors:  Ana Coto-Montes; Jose A Boga; Dun X Tan; Russel J Reiter
Journal:  Int J Mol Sci       Date:  2016-10-24       Impact factor: 5.923

4.  Melatonin for Atypical Antipsychotic-Induced Metabolic Adverse Effects: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Ashwin Kamath; Zahoor Ahmad Rather
Journal:  Biomed Res Int       Date:  2018-02-21       Impact factor: 3.411

Review 5.  Does Melatonin and Melatonin Agonists Improve the Metabolic Side Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Stanley C Igwe; Francesco Brigo
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-08-31       Impact factor: 2.582

Review 6.  The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.

Authors:  Mark R Libowitz; Erika L Nurmi
Journal:  Front Psychiatry       Date:  2021-03-12       Impact factor: 4.157

Review 7.  Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists.

Authors:  Simone Pisano; Gennaro Catone; Stefania Veltri; Valentina Lanzara; Marco Pozzi; Emilio Clementi; Raffaella Iuliano; Maria Pia Riccio; Sonia Radice; Massimo Molteni; Annalisa Capuano; Antonella Gritti; Giangennaro Coppola; Annarita Milone; Carmela Bravaccio; Gabriele Masi
Journal:  Ital J Pediatr       Date:  2016-05-21       Impact factor: 2.638

8.  Can melatonin prevent or improve metabolic side effects during antipsychotic treatments?

Authors:  Maria-Cristina Porfirio; Juliana Paula Gomes de Almeida; Maddalena Stornelli; Silvia Giovinazzo; Diane Purper-Ouakil; Gabriele Masi
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-10       Impact factor: 2.570

Review 9.  The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy.

Authors:  Eduardo Spinedi; Daniel P Cardinali
Journal:  Int J Endocrinol       Date:  2018-07-25       Impact factor: 3.257

Review 10.  Role of biological rhythm dysfunction in the development and management of bipolar disorders: a review.

Authors:  Yiming Chen; Wu Hong; Yiru Fang
Journal:  Gen Psychiatr       Date:  2020-02-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.